Prospective Integration of Patient Preferences Into Adjuvant Therapy Decisions for Older Women With Early-Stage Hormone Receptor-Positive Breast Cancer Adjuvant Therapy Decisions in Breast Cancer
Andrea M. Brown(Johns Hopkins University), Jean L. Wright(University of North Carolina at Chapel Hill), Hanh-Tam Tran, Larissa A. Korde(National Cancer Institute), Victoria Croog(Johns Hopkins University), Maureen O’Donnell, Sara R. Alcorn(University of Minnesota), Keara English, C.-F. Westin(Brigham and Women's Hospital), Mary Wilkinson(Johns Hopkins University), Princess Mark-Adjeli(Johns Hopkins University)
Cited by 1
Related Papers
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury
|Brain Imaging and Behavior|2012|935
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
|Practical Radiation Oncology|2018|615
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409